CAMP4 Therapeutics (CAMP)
Antisense RNA medicines designed to restore protein expression in genetic diseases.
Something off on this page? Send us feedback.
Develops antisense oligonucleotide medicines that increase protein expression from a functioning gene copy, using its RAP Platform to map regulatory RNAs. The business is pre-commercial, with research collaborations and potential licensing economics supplying revenue rather than product sales.
Develops antisense oligonucleotides through the RAP Platform, which maps locally acting regulatory RNAs and designs gene-specific candidates to increase protein output from a patient’s functioning gene copy. The approach targets haploinsufficient and partial loss-of-function disorders, with research and early candidate discovery also carried out for collaborators. Operations are primarily in the United States, alongside an Australian subsidiary and an international trial strategy.
CMP-002, the program for SYNGAP1-related disorder, is internally prioritized and designed to raise SYNGAP protein levels; the urea-cycle-disorders program is being considered for partnership after internal investment paused. No therapy is approved or commercially marketed. Revenue comes from research funding and collaboration economics, while partners can take responsibility for later development, regulatory work, manufacturing, and commercialization.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $87.1M · Total debt $2.4M · Total assets $93.4M · Shareholders' equity −$693.0K
- Revenue
- $1.8M
- Operating income
- −$13.4M
- Net income
- −$33.5M
No dividends on record.
| Institutions47 holders · as of Mar 31, 2026 | 63.40% | 39.78M shares | |
| Insiders12 holders · as of Sep 2, 2026 | 9.34% | 5.86M shares | |
| Strategic holders3 holders · as of Aug 19, 2026 | 12.40% | 7.78M shares | |
| Otherremainder | 14.86% | 9.32M shares |
62.75M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (62.75M in the company's Sep 3, 2026 report, 21.24M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Janus Henderson Group PLCInstitution | 10.05% | 6.31M | 13Fas of Mar 31, 2026 |
5Am Venture Management, LLCInstitution | 9.35% | 5.87M | 13Fas of Mar 31, 2026 |
FMR LLCInstitution | 7.86% | 4.93M | 13Fas of Mar 31, 2026 |
Coastlands Capital LPInstitution | 7.79% | 4.89M | 13Gfiled Dec 11, 2025 ↗ |
Vivo Capital, LLCInstitution | 6.77% | 4.25M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Kelly Gold | officer: Chief Financial Officer | +10,000 | $3.96 |
| Aug 27, 2026 | Andrew J. Schwab | director | −400,000 | $4.04 |
| Aug 24, 2026 | Andrew J. Schwab | director | −10 | $4.50 |
| Aug 21, 2026 | Andrew J. Schwab | director | −32,018 | $4.50 |
| Aug 20, 2026 | Andrew J. Schwab | director | −114,700 | $4.54 |
- Stoke Therapeutics
Direct SYNGAP1 ASO rival built on a protein-upregulation platform.
- Acadia Pharmaceuticals
Co-developer of a competing SYNGAP1 ASO with rare-disease commercial reach.
- Biogen
Intrathecal ASOs that increase protein output in pediatric genetic CNS disease.
- Wave Life Sciences
RNA-editing and splicing therapies that restore protein in genetic disease.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CAMP4 Therapeutics | $3.83 | +0.79% | $80.7M | — | — | 19.1 | +18.8% |
| Stoke Therapeutics | $30.70 | +0.52% | $1.97B | — | — | 71.3 | −32.5% |
| Acadia Pharmaceuticals | $28.93 | −0.03% | $4.95B | 13.0 | 32.5 | 4.4 | +16.4% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Wave Life Sciences | $4.80 | −1.44% | $961.6M | — | — | 14.7 | −73.9% |
| Median | 26.2 | 24.7 | 9.5 | −14.5% |